CDXS Codexis Forecast, Technical & Fundamental Analysis
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes... Show more
CDXS is expected to report earnings to fall 24.38% to -9 cents per share on October 29
Q3'26
Est.
$-0.10
Q2'26
Beat
by $0.01
Q1'26
Beat
by $0.06
Q4'25
Beat
by $0.15
Q3'25
Missed
by $0.07
The last earnings report on August 11 showed earnings per share of -12 cents, beating the estimate of -14 cents. With 845.69K shares outstanding, the current market capitalization sits at 182.87M.
A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then AXON could also see price increases.
CDXS's Stochastic Oscillator penetrating overbought zone
The Stochastic Oscillator for CDXS moved into overbought territory on August 21, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDXS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CDXS broke above its upper Bollinger Band on August 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CDXS entered a downward trend on August 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CDXS's RSI Oscillator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 12, 2026. You may want to consider a long position or call options on CDXS as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CDXS just turned positive on August 11, 2026. Looking at past instances where CDXS's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CDXS advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.549) is normal, around the industry mean (20.145). P/E Ratio (0.000) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (1.965) is also within normal values, averaging (444.692).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CDXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
